Support teaching, research, and patient care.
Biological bases of depressive disorders;, glucocorticoid/dopamine interactions in delusional depression;, pharmacologic treatment of depressive disorders.
Identifying Biological Markers for Severe Depression Not Recruiting
The primary objective of this study is to investigate the biological components of major depression. The investigators are particularity interested in genetic variation and how it contributes to cortisol (because cortisol is higher in severe depression than mild depression or healthy controls) and how it contributes to clinical symptoms, especially suicidal ideation/behavior and psychosis.
Stanford is currently not accepting patients for this trial. For more information, please contact Maureen H Chang, B.S., 650-725-4620.
View full details
Opiate Suicide Study in Patients With Major Depression Not Recruiting
To explore whether intravenous ketamine followed by buprenorphine produces more rapid and sustained anti-suicidal effects than ketamine followed by placebo, investigators will conduct a single study that will take approximately 2.5 years to complete. 60 subjects (60 infusions) or approximately 24 infusions per year.
Stanford is currently not accepting patients for this trial. For more information, please contact Jessica Hawkins, 650-723-8323.
Clinical and Biological Characteristics of Psychotic Depression Not Recruiting
The primary objective of this study is to investigate the relationships among findings in structural and functional neuroimaging, cognitive testing and HPA (hypothalamic-pituitary-adrenal) axis dysregulation in psychotic depression.
Stanford is currently not accepting patients for this trial. For more information, please contact Lakshika Tennakoon, 650-723-3305.
